Does Anthem (Elevance Health) Cover Enclomiphene Citrate?

What Is Enclomiphene Citrate and Why Do Physicians Prescribe It?

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM) that stimulates the hypothalamic-pituitary axis to raise endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn raises serum testosterone. Unlike exogenous testosterone replacement therapy (TRT), enclomiphene preserves spermatogenesis, making it particularly relevant for men who want to maintain fertility while correcting low testosterone 1.

Kim et al. (BJU Int, 2016, N=124) randomized men with secondary hypogonadism to enclomiphene citrate 12.5 mg or 25 mg versus transdermal testosterone. At 3 months, both enclomiphene doses restored morning testosterone to the normal range (300 to 1000 ng/dL), while sperm concentrations fell significantly in the testosterone arm (P<0.01) but held steady with enclomiphene 1. That fertility-preservation signal is the primary clinical reason prescribers choose enclomiphene over standard TRT.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism notes that gonadotropin-stimulating agents are appropriate in men with secondary hypogonadism who wish to preserve fertility 2. Anthem's own medical policy language mirrors this framing: coverage for non-standard testosterone-raising agents is generally conditioned on a confirmed secondary (hypogonadotropic) etiology, not primary testicular failure.

Serum testosterone below 300 ng/dL on two morning draws, paired with low or inappropriately normal LH and FSH, constitutes the laboratory threshold most Anthem clinical policies require before any testosterone-axis drug qualifies for coverage 3. Get those labs before submitting the PA request. A single low-testosterone result without gonadotropin data is the single most common reason for an immediate denial.

Is Enclomiphene Citrate FDA-Approved?

Enclomiphene's regulatory history directly affects how Anthem codes the drug. Androxal (enclomiphene citrate), developed by Repros Therapeutics, received a complete response letter from the FDA in 2013 and again in 2014, stalling formal NDA approval for secondary hypogonadism 4. The drug has never received full FDA approval for any indication.

That unapproved status is clinically significant for two reasons. First, Anthem's formulary management teams classify enclomiphene as off-label for secondary hypogonadism. Second, coverage of off-label drugs under commercial plans is governed by the insurer's medical necessity criteria and the "compendia" list, which includes publications such as DRUGDEX and the AHFSfirstline 5. Enclomiphene's published Phase III data (including the Kim et al. trial) support compendia recognition in at least some editions, which strengthens an appeal argument considerably.

Prescribers should document the off-label use explicitly in the chart note and cite the peer-reviewed evidence. Anthem reviewers who see only a diagnosis code without supporting literature are more likely to deny. Attaching the Kim et al. abstract or a PubMed link to the PA submission has, in clinical practice, improved first-pass approval rates.

Anthem's Formulary Position for Enclomiphene Citrate

Most Anthem commercial formularies do not list enclomiphene citrate as a preferred or non-preferred branded product. The drug instead falls into one of two buckets depending on the specific plan: non-preferred specialty tier (Tier 4 or 5) or outright non-formulary status 6.

Non-formulary does not mean uncoverable. Anthem's pharmacy benefit managers (typically IngenioRx for commercial lines) allow a formulary exception request, which is essentially a PA with an added burden of proof: the member must demonstrate that all formulary alternatives are contraindicated, have failed, or are clinically inappropriate. For enclomiphene specifically, the "clinically inappropriate" argument is strongest when fertility preservation is documented. A 2020 study in Fertility and Sterility (N=60) confirmed that clomiphene-related SERMs maintain sperm parameters better than exogenous testosterone over 6 months 7, and that data can anchor the formulary exception narrative.

Anthem plan formularies change on January 1 of each plan year and sometimes at mid-year. Always pull the current Evidence of Coverage (EOC) document from Anthem's member portal or call the pharmacy benefit number on the back of the insurance card before submitting a PA. Stale formulary data is the second most common reason PA submissions are incomplete.

Prior Authorization Criteria: What Anthem Typically Requires

Anthem rates as a "moderate" difficulty insurer for enclomiphene PA. The criteria are specific but not unusual for a specialty-tier off-label drug. Based on published Anthem clinical policy bulletins and peer-reviewed analysis of insurer coverage patterns, the typical required documentation includes:

Diagnosis confirmation. ICD-10 code E23.0 (hypopituitarism) or E29.1 (testicular hypofunction) with chart notes specifying secondary (central) etiology. A pituitary MRI ruling out macro-adenoma may be requested if prolactin is elevated 8.

Laboratory thresholds. Two morning serum total testosterone values below 300 ng/dL drawn at least one week apart, with simultaneous LH and FSH in the low-normal or low range. Free testosterone below 65 pg/mL adds support. The American Urological Association 2018 guideline on testosterone deficiency specifies the same two-sample threshold 9.

Fertility intent. A documented clinical note stating the patient wishes to preserve spermatogenesis. This single element converts the case from a general hypogonadism claim into a fertility-preservation argument, which is the clinically differentiated ground on which enclomiphene beats standard TRT for coverage purposes.

Prescriber specialty. Anthem occasionally requires the prescribing physician to be a urologist, endocrinologist, or reproductive endocrinologist. Primary care prescriptions are not automatically disqualified but may trigger a peer-to-peer review request.

Absence of contraindications. The prescriber should confirm no active liver disease, no history of thromboembolic events, and no concurrent use of medications that substantially alter CYP3A4 metabolism, since clomiphene isomers are hepatically metabolized 10.

Step Therapy: What Must You Try Before Enclomiphene?

Step therapy is the most common source of frustration for patients seeking enclomiphene through Anthem. The typical requirement mandates a trial of at least one, and sometimes two, preferred testosterone products before enclomiphene is approved.

Preferred testosterone products on most Anthem commercial formularies in 2024-2025 include testosterone cypionate injection (generic, Tier 1 or 2), testosterone enanthate injection (generic), and at least one topical testosterone gel such as AndroGel 1.62% (Tier 3). Testosterone undecanoate (Jatenzo, Tlando) sits at non-preferred on most plans and does not always count as a qualifying step-therapy trial.

The step-therapy bypass pathway is available when standard testosterone is contraindicated or clinically inappropriate. Documented infertility concern, elevated hematocrit at baseline (above 52%), documented erythrocytosis risk, or a sleep apnea diagnosis that worsens with exogenous testosterone all constitute bypass arguments supported by clinical evidence 11. The American Urological Association guideline (2018) specifically states that testosterone therapy is relatively contraindicated in men who desire fertility in the near term 9.

Several states have enacted step-therapy reform laws that limit an insurer's ability to require more than one step before approving a clinically differentiated drug. As of 2024, at least 31 states have some form of step-therapy protection law 12. If the patient's Anthem plan is a fully-insured commercial product (not a self-insured ERISA plan), state step-therapy laws apply and can be cited in an appeal.

How to Submit the Prior Authorization Request

A complete PA packet reduces denial rates substantially. Compile the following before calling or submitting through Anthem's ProviderAccess Online portal:

1. Two morning testosterone labs with dates, collection times, and simultaneous LH/FSH.
2. A chart note clearly stating secondary hypogonadism etiology and fertility intent.
3. A letter of medical necessity citing Kim et al. (BJU Int, 2016) and the Endocrine Society guideline 2.
4. Documentation of any contraindication to exogenous testosterone (step-therapy bypass).
5. If step therapy is required: records of the qualifying testosterone trial, including start/stop dates, doses used, adverse effects, or documented inadequate response.

Anthem's standard PA turnaround is 72 hours for non-urgent requests and 24 hours for urgent (expedited) requests. Expedited status is appropriate when delay would seriously jeopardize the patient's health, as defined under 45 CFR 147.136 13.

The framework above (two-lab threshold plus fertility-intent note plus bypass documentation) represents the HealthRX clinical team's distillation of the most common PA failure points across Anthem submissions reviewed internally, and serves as the submission checklist our affiliated providers use before clicking "submit."

What Happens After a Denial: The Anthem Appeal Process

Anthem denials for enclomiphene are not final. The appeals pathway has three sequential levels, and each step has a real reversal rate when documentation improves.

Level 1: Internal Anthem Appeal. Submit within 180 days of the denial notice (check your specific EOC; some plans allow only 60 days for post-service claims). Include all original PA documentation plus any new clinical evidence. Request a peer-to-peer call between the treating physician and the Anthem medical reviewer. Peer-to-peer conversations improve approval rates substantially when the prescriber can articulate the fertility-preservation rationale in real time.

Level 2: Second-Level Internal Appeal. If Level 1 fails, Anthem allows a second internal review. New supporting evidence should be added, such as a semen analysis showing baseline sperm parameters the patient wants to protect, or a reproductive endocrinology consultation note.

Level 3: Independent Review Organization (IRO). After exhausting internal appeals, fully-insured commercial plan members have the right to an external review by a state-certified IRO under the ACA's external review provisions 14. The IRO reviewer is a physician with no financial relationship to Anthem. IRO decisions binding on Anthem are the strongest reversal tool available, and approval rates at the IRO stage for off-label oncology and endocrine drugs hover around 39 to 47% based on published external review outcome data 15.

Self-insured ERISA plans (common in large employers) are not subject to state IRO laws. The external review option still exists under ERISA, but the enforcement mechanism differs. An ERISA plan participant can file suit in federal district court after exhausting internal appeals, and the plan's denial will be reviewed under an "arbitrary and capricious" standard unless the plan document does not grant discretionary authority to the administrator 16.

Enclomiphene Dosing Context for PA and Appeal Letters

Anthem reviewers expect to see a specific, evidence-based dosing regimen in the PA or appeal letter. Vague prescriptions increase denial probability. Kim et al. used 12.5 mg and 25 mg once-daily oral dosing in their Phase III trial 1. A 2013 Repros Therapeutics Phase III study (N=195) showed that enclomiphene 12.5 mg daily for 6 months raised testosterone from a mean of 237 ng/dL to 414 ng/dL while maintaining sperm concentration above the WHO normal threshold of 15 million/mL 17. Citing that specific datum (414 ng/dL mean at 6 months, sperm concentration preserved) in the letter of medical necessity gives the Anthem reviewer a quantifiable outcome expectation rather than a general statement of efficacy.

Standard clinical practice at HealthRX-affiliated practices starts at 12.5 mg daily for 4 weeks, checks a morning testosterone and LH at week 4, then titrates to 25 mg if testosterone remains below 350 ng/dL. Total monitoring labs at weeks 4, 12, and 24 align with the Endocrine Society guideline monitoring schedule for testosterone therapy 2.

Manufacturer Savings Cards and Cash-Pay Options

Enclomiphene does not have a widely promoted manufacturer copay card program comparable to those offered for branded GLP-1 drugs. The drug's unapproved regulatory status and the small number of branded versions in circulation mean that savings programs are limited.

Cash-pay compounded enclomiphene citrate is available through 503A compounding pharmacies. Prices vary by dose and pharmacy; 12.5 mg capsules typically range from $60 to $150 per 30-day supply depending on geography and compounding pharmacy overhead. The FDA has not taken enforcement action against 503A pharmacies compounding enclomiphene for individual patient prescriptions, though the agency's position on bulk drug substances used in compounding evolves periodically 18.

Patients on Medicaid or Medicare cannot legally use a commercial manufacturer coupon card for any drug covered under a federal program, per anti-kickback statute provisions 19. Commercial insurance members may use copay cards if the card is not expressly prohibited by their plan's coordination-of-benefits clause.

State-Specific Anthem Variations That Affect Coverage

Anthem (Elevance Health) operates under different subsidiary names by state: Anthem Blue Cross (California), Anthem Blue Cross Blue Shield (multiple states), Empire BlueCross BlueShield (New York), and others. Formulary decisions are partly standardized nationally and partly set at the regional affiliate level.

New York and California both have external review laws that apply to fully-insured commercial plans and tend to produce favorable IRO outcomes for off-label drugs supported by peer-reviewed evidence 15. Georgia and Indiana, where Anthem has large commercial market shares, follow the federal ACA external review framework 14.

The Endocrine Society's position statement on testosterone therapy, updated in 2020, specifically notes that SERMs including clomiphene and its isomers are an "acceptable alternative" in men with secondary hypogonadism who wish to father children 20. That language is directly usable in an appeal letter addressed to any Anthem regional affiliate.

Monitoring Requirements Anthem May Request at Renewal

PA approvals for enclomiphene are typically granted for 12 months. Renewal requires updated lab documentation. Anthem's clinical reviewers at renewal will generally want to see:

Morning serum testosterone in the 300 to 1000 ng/dL range (confirming drug efficacy), hematocrit below 54% (ruling out erythrocytosis), and a brief clinical note confirming ongoing fertility intent or continued clinical necessity 21. A PSA check is occasionally required for men over 40, mirroring the Endocrine Society's testosterone monitoring recommendation 2.

Estradiol monitoring is not typically required by Anthem at renewal but is standard clinical practice. Enclomiphene modestly raises estradiol by increasing aromatization from higher testosterone levels; values above 60 pg/mL may warrant dose adjustment or a short anastrozole trial at 0.5 mg twice weekly 22. Including estradiol results voluntarily in renewal documentation signals thorough clinical management and can preempt a medical reviewer's concern about estrogenic side effects.